StockNews.AI
IART
StockNews.AI
71 days

INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Integra LifeSciences Holdings Corp. and Encourages Long-Term Investors to Contact the Firm – IART

1. Kaskela Law is investigating fiduciary duty claims against IART. 2. A securities fraud complaint has been filed for misleading statements. 3. IART paused production at its Boston Facility following FDA inspections. 4. The company expects a $22 million impairment charge due to product recalls. 5. IART shares fell significantly after recent negative disclosures.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The ongoing investigations and significant product recalls have harmed investor trust, evidenced by major stock price declines following each disclosure, such as 20% drop on May 23, 2023.

How important is it?

Legal investigations can significantly affect shareholder confidence and stock price in the short term, due to implications of fiduciary duty breaches and potential legal liabilities.

Why Short Term?

The short-term impact is likely due to ongoing investigations and potential legal ramifications that could result in immediate negative sentiment in IART's stock performance.

Related Companies

JNJMDTABT
Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Integra LifeSciences Holdings Corp. (NASDAQ:IART) ("Integra") on behalf of the company's long-term investors.Click here to receive additional information about your legal rights and options: https://kaskelalaw.com/cases/integra-lifesciences/Recently a securities fraud complaint was filed against Integra on behalf of investors who purchased shares of the company's stock between March 11, 2019 and May 22, 2023. According to the complaint, during that time period Integra and certain of the company's senior executive officers issued a series of materially false and misleading statements to investors concerning the company's business, operations and prospects.As further detailed in the complaint, on October 9, 2018, the FDA began an inspection of the company's Boston Facility, during which it observed that Integra's quality systems and manufacturing conditions were "not in conformity with the current good manufacturing practice requirements of the Quality System Regulation."On April 26, 2023, Integra revealed that it had paused production at the Boston Facility. The company also disclosed declining operating margins for the quarter and flat revenue growth projections, which it attributed to the manufacturing stoppage. As a result of these disclosures, shares of Integra's common stock declined by $4.64 per share, or 8% in value, to close at $54.20 per share on unusually heavy trading volume. Later that day Integra further revealed that, on March 1, 2023, the FDA had commenced another inspection of the Boston Facility and that the company expected to receive another Form 483 as a result of that inspection.Then, on May 23, 2023, the Company announced a "recall" of products manufactured at its Boston Facility between March 2018 and May 2023. Integra disclosed that it had determined that the Boston Facility deviated from good manufacturing practices in testing for bacterial endotoxin and allowed the release of products with unsafe levels of endotoxins. Integra further disclosed that it expected to take a $22 million impairment charge in the second quarter due to the inventory write-off. Following these additional disclosures, shares of Integra's common stock fell an additional $10.24 per share, or 20% in value, to close on May 23, 2023 at $40.48 per share, again on unusually heavy trading volume.The investigation seeks to determine whether Integra's officers and directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.Current Integra shareholders who purchased or acquired IART shares prior to April 26, 2023 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 - 0750 for additional information about this investigation and their legal rights and options.Alternatively, investors may submit their information to the firm by clicking on the following link (or if necessary, by copying and pasting the link into your browser):https://kaskelalaw.com/cases/integra-lifesciences/Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.CONTACT:KASKELA LAW LLCD. Seamus Kaskela, Esq. ([email protected]) Adrienne Bell, Esq. ([email protected]) 18 Campus Blvd., Suite 100 Newtown Square, PA 19073 (888) 715 - 1740 (484) 229 - 0750 www.kaskelalaw.comThis notice may constitute attorney advertising in certain jurisdictions.SOURCE: Kaskela Law LLC

Related News